Common cold: Difference between revisions
imported>Robert Badgett (Started prevention) |
imported>Robert Badgett |
||
| Line 3: | Line 3: | ||
==Diagnosis== | ==Diagnosis== | ||
The [[United States]] [[Food and Drug Administration]] has approved xTAG™ Respiratory Viral Panel (RVP) for | The [[United States]] [[Food and Drug Administration]] has approved xTAG™ Respiratory Viral Panel (RVP) for detects the viruses:<ref name="urlK063765">{{cite web |url=http://www.fda.gov/cdrh/mda/docs/K063765.html |title=New Device Approval - xTAG™ Respiratory Viral Panel (RVP) - K063765 |author=Anonymous |authorlink= |coauthors= |date=2008 |format= |work= |publisher=Food and Drug Administration |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=2008-11-04}}</ref> | ||
* [[influenza A virus]] | |||
* [[influenza B virus]] | |||
* [[respiratory syncytial virus]] | |||
* [[adenovirus]] | |||
* [[parainfluenza virus]] types 1, 2, and 3 | |||
* [[rhinovirus]] and [[enterovirus]] (but cannot distinguish between them) | |||
* [[human metapneumovirus]] | |||
==Treatment== | ==Treatment== | ||
Revision as of 10:11, 30 September 2009
The common cold is a "catarrhal[1] disorder of the upper respiratory tract, which may be viral, a mixed infection, or an allergic reaction. It is marked by acute coryza,[2] slight rise in temperature, chilly sensations, and general indisposition."[3]
Diagnosis
The United States Food and Drug Administration has approved xTAG™ Respiratory Viral Panel (RVP) for detects the viruses:[4]
- influenza A virus
- influenza B virus
- respiratory syncytial virus
- adenovirus
- parainfluenza virus types 1, 2, and 3
- rhinovirus and enterovirus (but cannot distinguish between them)
- human metapneumovirus
Treatment
Naproxen, a non-steroidal anti-inflammatory agent, may[5] or may not[6] reduce "symptoms of headache, malaise, myalgia, and cough".
Regarding over-the-counter (OTC) medications, "there is no good evidence for or against the effectiveness of OTC medicines in acute cough" according to a systematic review by the Cochrane Collaboration.[7]
"P. sidoides may be effective in alleviating symptoms of acute rhinosinusitis and the common cold in adults, but doubt exists," according to a systematic review by the Cochrane Collaboration.[8]
Prevention
A patent was granted for a vaccine in 1936.[9] The proposed vaccine was oral and its target was pneumococcal antigens.
References
- ↑ Inflammation of the nose and throat with increased production of mucus.
- ↑ inflammation of the mucous membrane lining the nose (usually associated with nasal discharge).
- ↑ Anonymous (2024), Common cold (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Anonymous (2008). New Device Approval - xTAG™ Respiratory Viral Panel (RVP) - K063765. Food and Drug Administration. Retrieved on 2008-11-04.
- ↑ Sperber SJ, Hendley JO, Hayden FG, Riker DK, Sorrentino JV, Gwaltney JM (1992). "Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial". Ann. Intern. Med. 117 (1): 37-41. PMID 1317694. [e]
- ↑ Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006362. PMID 19588387
- ↑ Smith SM, Schroeder K, Fahey T (2008). "Over-the-counter medications for acute cough in children and adults in ambulatory settings". Cochrane Database Syst Rev (1): CD001831. DOI:10.1002/14651858.CD001831.pub3. PMID 18253996. Research Blogging.
- ↑ Timmer A, Günther J, Rücker G, Motschall E, Antes G, Kern WV (2008). "Pelargonium sidoides extract for acute respiratory tract infections". Cochrane Database Syst Rev (3): CD006323. DOI:10.1002/14651858.CD006323.pub2. PMID 18646148. Research Blogging.
- ↑ Powell, Horace. (1936) Common Cold Antigen. Google Patents.